XBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Xenetic Biosciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$1.93−0.06 (-3.02%)
Close on Oct 19, 2026
- Market cap
- $4.43M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$2.28 (−54.16%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Xenetic Biosciences, Inc. grew revenue 33.3% to $3.26M over the twelve months to Jun 30, 2026.
Revenue
$3.26M
+33.3% vs. a year earlier
Operating income
-$2.64M
TTM Q2 2026
EPS, diluted
-$1.21
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $4.43M
- P/E ratio
- –
- Price to sales
- 1.36
- Price to book
- 0.73
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $3.26M
- Net income
- -$2.48M
- EPS, diluted
- -$1.21
- Book value per share
- $2.65
- Diluted shares
- 2M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$3.26M+33.3% YoY
Gross profit
–
Operating income
-$2.64M
Net income
-$2.48M
EPS, diluted
-$1.21
Free cash flow
–
Reported periodTrailing twelve months